vs

Side-by-side financial comparison of AGENUS INC (AGEN) and ATRenew Inc. (RERE). Click either name above to swap in a different company.

ATRenew Inc. is the larger business by last-quarter revenue ($43.2M vs $34.2M, roughly 1.3× AGENUS INC). ATRenew Inc. runs the higher net margin — 16.9% vs -31.0%, a 47.9% gap on every dollar of revenue.

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.

ATRenew Inc. operates a leading pre-owned consumer electronics transaction and servicing ecosystem primarily in China. Its core services include end-to-end device recycling, professional quality inspection, certified refurbishment, and resale of smartphones, laptops, tablets and other digital products, serving both individual consumers and enterprise clients across domestic and select Southeast Asian markets.

AGEN vs RERE — Head-to-Head

Bigger by revenue
RERE
RERE
1.3× larger
RERE
$43.2M
$34.2M
AGEN
Higher net margin
RERE
RERE
47.9% more per $
RERE
16.9%
-31.0%
AGEN

Income Statement — Q4 FY2025 vs Q1 FY2023

Metric
AGEN
AGEN
RERE
RERE
Revenue
$34.2M
$43.2M
Net Profit
$-10.6M
$7.3M
Gross Margin
Operating Margin
42.1%
Net Margin
-31.0%
16.9%
Revenue YoY
27.5%
Net Profit YoY
77.3%
EPS (diluted)
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGEN
AGEN
RERE
RERE
Q4 25
$34.2M
Q3 25
$30.2M
Q2 25
$25.7M
Q1 25
$24.1M
Q4 24
$26.8M
Q3 24
$25.1M
Q2 24
$23.5M
Q1 24
$28.0M
Net Profit
AGEN
AGEN
RERE
RERE
Q4 25
$-10.6M
Q3 25
$63.9M
Q2 25
$-30.0M
Q1 25
$-26.4M
Q4 24
$-46.8M
Q3 24
$-67.2M
Q2 24
$-54.8M
Q1 24
$-63.5M
Gross Margin
AGEN
AGEN
RERE
RERE
Q4 25
Q3 25
97.9%
Q2 25
99.1%
Q1 25
99.4%
Q4 24
99.6%
Q3 24
99.4%
Q2 24
99.5%
Q1 24
99.6%
Operating Margin
AGEN
AGEN
RERE
RERE
Q4 25
42.1%
Q3 25
-15.0%
Q2 25
-65.0%
Q1 25
-55.3%
Q4 24
-96.5%
Q3 24
-125.5%
Q2 24
-128.4%
Q1 24
-117.4%
Net Margin
AGEN
AGEN
RERE
RERE
Q4 25
-31.0%
Q3 25
211.4%
Q2 25
-116.8%
Q1 25
-109.6%
Q4 24
-174.4%
Q3 24
-267.7%
Q2 24
-233.1%
Q1 24
-226.6%
EPS (diluted)
AGEN
AGEN
RERE
RERE
Q4 25
$0.09
Q3 25
$1.94
Q2 25
$-1.00
Q1 25
$-1.03
Q4 24
$-1.95
Q3 24
$-3.08
Q2 24
$-2.52
Q1 24
$-3.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGEN
AGEN
RERE
RERE
Cash + ST InvestmentsLiquidity on hand
$3.0M
$228.0M
Total DebtLower is stronger
$44.7M
Stockholders' EquityBook value
$-271.1M
$557.1M
Total Assets
$226.8M
$722.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGEN
AGEN
RERE
RERE
Q4 25
$3.0M
Q3 25
$3.5M
Q2 25
$9.5M
Q1 25
$18.5M
Q4 24
$40.4M
Q3 24
$44.8M
Q2 24
$93.7M
Q1 24
$52.9M
Total Debt
AGEN
AGEN
RERE
RERE
Q4 25
$44.7M
Q3 25
$34.2M
Q2 25
$33.9M
Q1 25
$33.6M
Q4 24
$33.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AGEN
AGEN
RERE
RERE
Q4 25
$-271.1M
Q3 25
$-274.1M
Q2 25
$-354.6M
Q1 25
$-341.8M
Q4 24
$-326.4M
Q3 24
$-292.3M
Q2 24
$-241.3M
Q1 24
$-201.4M
Total Assets
AGEN
AGEN
RERE
RERE
Q4 25
$226.8M
Q3 25
$233.9M
Q2 25
$185.2M
Q1 25
$200.2M
Q4 24
$226.3M
Q3 24
$238.5M
Q2 24
$292.4M
Q1 24
$256.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGEN
AGEN
RERE
RERE
Operating Cash FlowLast quarter
$-16.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGEN
AGEN
RERE
RERE
Q4 25
$-16.6M
Q3 25
$-14.7M
Q2 25
$-20.2M
Q1 25
$-25.6M
Q4 24
$-28.7M
Q3 24
$-53.3M
Q2 24
$-38.2M
Q1 24
$-38.2M
Free Cash Flow
AGEN
AGEN
RERE
RERE
Q4 25
Q3 25
Q2 25
$-20.2M
Q1 25
$-25.6M
Q4 24
$-28.7M
Q3 24
$-53.3M
Q2 24
$-38.6M
Q1 24
$-38.2M
FCF Margin
AGEN
AGEN
RERE
RERE
Q4 25
Q3 25
Q2 25
-78.7%
Q1 25
-106.5%
Q4 24
-107.0%
Q3 24
-212.2%
Q2 24
-164.4%
Q1 24
-136.5%
Capex Intensity
AGEN
AGEN
RERE
RERE
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.3%
Q3 24
0.0%
Q2 24
2.0%
Q1 24
0.1%
Cash Conversion
AGEN
AGEN
RERE
RERE
Q4 25
Q3 25
-0.23×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGEN
AGEN

Non Cash Royalty Revenue$31.1M91%
Other$3.2M9%

RERE
RERE

Segment breakdown not available.

Related Comparisons